Buprenorphine for opioid dependence

Expert Review of Neurotherapeutics

Volumn 9, Issue 5, 2009, Pages 609-616

  Ling, Walter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Buprenorphine; Heroin addiction; Opioid dependence; PharmacotherA y; Suboxone

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CLONIDINE; METHADONE; MORPHINE; NALOXONE; NALTREXONE; NORBUPRENORPHINE; OPIATE; PLACEBO;

CLINICAL TRIAL; DRUG ABUSE; DRUG APPROVAL; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; HEROIN DEPENDENCE; HUMAN; OPIOID DEPENDENCE; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; REVIEW; TREATMENT DURATION;

BUPRENORPHINE; CLINICAL TRIALS AS TOPIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 66249133702     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.26     Document Type: Review

References (49)

1. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55(5), 569-580 (1994).
2. Amass L, Ling W, Freese TE et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am.J. Addict. 13(Suppl. 1), S42-S66 (2004).
3. Ling W, Amass L, Shoptaw S et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 100(8), 1090-1100 (2005).
4. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatry 53(5), 401-407 (1996).
5. Schuh KJ, Johanson CE. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend. 56(1), 55-60 (1999).
6. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 70(2 SuppL), S39-S47 (2003).
7. Compton P, Ling W, Moody D, Chiang N. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend. 82(1), 25-31 (2006).
8. Compton P, Ling W, Chiang N, Moody DE, Huber A, Charuvastra C. Pharmacokinetics of buprenorphine: a comparison of sublingual tablet versus liquid after chronic dosing. J. Addict. Med. 1, 88-95 (2007).
9. Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 61(1), 85-94 (2000).
10. Hitzemann R, Chiang CN, Cerveny P et al. Buprenorphine-naloxone (4:1) combination - dose proportionality after sublingual administration (Abstract). Presented at: Proceedings of the 60th Annual Scientific Meeting of the College on Problems fo Drug Dependence. Scottsdale, AZ, USA 13-18 June 1998.
11. Jones ET, Mendelson J, Upton R. An open-label, partially blinded, balanced 4×4 latin square crossover study to evaluate the pharmacokinetic and dose-proportionality of buprenorphine when administered in sublingual tablets alone or in combination with naloxone in nondependent opiate users. NIDA Contract N01DA-4-8306Report, Pharmacokinetic and Pharmacodynamic Studies for Medication Development (1997).
12. Ciraulo DA, Hitzemann RJ, Somoza E et al. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.J. Clin. Pharmacol. 46(2), 179-192 (2006).
13. Jones RT, Mendelson J. Determination of buprenorphine mass balance. NIDA Contract N01DA-4-8306Report, Pharmacokinetic and Pharmacodynamic Studies for Medication Development (1997).
14. Amass L, Bickel WK, Higgins ST, Hughes JR. A preliminary investigation of outcome following gradual or rAβid buprenorphine detoxification.J. Addict. Dis. 13(3), 33-45 (1994).
15. Woody GE, Poole SA, Subramaniam G et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 300(17), 2003-2011 (2008).
16. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2, CD002207 (2008).
17. LingW, HillhouseM, Domier C et al.. Buprenorphine tAβering schedule and illicit opioid use. Addiction 104(2), 256-265 (2009).
18. Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on l00mg of daily methadone. Drug Alcohol Depend. 90(2-3), 261-269 (2007).
19. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch. Gen. Psychiatry 35(4), 501-516 (1978).
20. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 40(1), 17-25 (1995).
21. Ling W, Charuvastra C, Collins JF et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93 (4), 475-486 (1998).
22. Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science 207(4431), 657-659 (1980).
23. Mello NK, Bree MP, Mendelson JH. Comparison of buprenorphine and methadone effects on opiate self-administration in primates. J. Pharmacol. Exp. Ther. 225(2), 378-386 (1983).
24. Amass L, Kamien JB, Branstetter SA, Mikulich SK. A controlled comparison of the buprenorphine-naloxone tablet and methadone for opioid maintenance treatment: interim results. In: Problems of Drug Dependence NIDA Research MonogrAβh Series, No. 180. NIH Publication No. 00-4737. Harris LS (Ed.). US Government Printing Office, Washington DC, USA 161 (2000).
25. O'Connor PG, Oliveto AH, Shi JM et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am. J. Med. 105(2), 100-105 (1998).
26. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin. Pharmacol. Ther. 43(1), 72-78 (1988).
27. Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment, including buprenorphine/naloxone. Ann. Pharmacother. 36(2), 312-321 (2002).
28. Chawarski MC, Schottenfeld RS, O'Connor PG, Pakes J. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug Alcohol Depend. 55(1-2), 157-163 (1999).
29. Pickworth WB, Johnson RE, Holicky BA, Cone EJ. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin. Pharmacol. Ther. 53(5), 570-576 (1993).
30. Chiang CN, Hawks R. Development of a buprenorphine-naloxone combination drug for the treatment of drug addiction. In: Problems of Drug Dependence NIDA Research MonogrAβh Series, No. 141. Harris LS (Ed.). National Institute on Drug Abuse, MD, USA 458 (1994).
31. Nath RP, Upton RA, Everhart ET et al. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J. Clin. Pharmacol. 39(6), 619-623(1999).
32. Preston KL, Bigelow GE, Liebson IA. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Bed.) 94(4), 484-490 (1988).
33. Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine/ naloxone in opioid-dependent humans. Psychopharmacology (Berl.) 154(3), 230-242 (2001).
34. Strain EC, Stoller K, Walsh SL, Bigelow GE. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berl.) 148(4), 374-383 (2000).
35. Mendelson J, Jones RT, Welm S et al. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl.) 141(1), 37-46 (1999).
36. Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. Am. J. Addict. 13(Suppl. 1), S17-S28 (2004).
37. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relAβse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet361(9358), 662-668 (2003).
38. Petitjean S, Stohler R, Deglon JJ et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 62(1), 97-104 (2001).
39. Lintzeris N, Ritter A, Dunlop A, Muhleisen P. Training primary health care professionals to provide buprenorphine and LAAM treatment. Subst. Abus. 23(4), 245-254 (2002).
40. O'Connor PG. Treating opioid dependence - new data and new opportunities. N. Engl. J. Med. 343(18), 1332-1334 (2000).
41. Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: reaching new patient populations. Am. J. Psychiatry 158(8), 1200-1204 (2001).
42. Bridge TP, Fudala PJ, Herbert S, Leiderman DB. Safety and health policy considerations related to the use of buprenorphine/ naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend. 70(2 Suppl), S79-S85 (2003).
43. Leshner AL Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting. Drug Alcohol Depend. 70(2 Suppl.), S103-S104 (2003).
44. Fudala PJ, Bridge TP, Herbert S et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N.Engl. J. Med. 349(10), 949-958 (2003).
45. Cicero TJ, Surratt HL, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J. Opioid Manag. 3(6), 302-308 (2007).
46. Bogenschutz M, Kushner R, Tonigan J, Woody G. Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults. Poster presented at: The College on Problems of Drug Dependence (CPDD) Annual Meeting San Juan, Puerto Rico, 14-19 June 2008.
47. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch. Intern. Med. 167(22), 2469-2475 (2007).
48. Jaffe JH, O'Keeffe CO. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 70(2 Suppl.), S3-S11 (2003).
49. Ling W, Smith D. Buprenorphine: blending practice and research. J.Subst. Abuse Treat. 23(2), 87-92 (2002).